{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Objective response is defined as having a complete response (CR) or a partial response (PR) according to the modified RECIST criteria for assessment of response in malignant pleural mesothelioma. CR is defined as the disappearance of all target lesions with no evidence of tumour elsewhere and PR is defined as at least a 30% reduction in the total tumour measurement. A confirmed response requires a repeat observation on two occasions 4 weeks apart.","groups":[{"description":"Vandetanib 300 mg/day oral","id":"OG000","title":"Vandetanib"},{"description":"Vinorelbine 30 mg/m2 iv, administrated weekly","id":"OG001","title":"Vinorelbine"}],"paramType":"NUMBER","populationDescription":"Only patients in the evaluable for efficacy population were included. It was defined as all treated patients with no major deviations from the eligibility criteria affecting the evaluation of efficacy, who completed at least 2 cycles (unless progressive disease occurred at cycle 1) and who had at least one post-treatment tumour assessment.","reportingStatus":"POSTED","timeFrame":"Assessed at 2 months.","title":"Number of Participants With Objective Response.","type":"SECONDARY","unitOfMeasure":"Participants"}